1-7 of 7
Alexander M. Lesokhin
Close
Sort by
Journal Articles

Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

Anna J. Howard, Isabel Concepcion, Alice X. Wang, Issam S. Hamadeh, Malin Hultcrantz, Sham Mailankody, Carlyn Tan, Neha Korde, Alexander M. Lesokhin, Hani Hassoun, Urvi A. Shah, Kylee H. Maclachlan, Sridevi Rajeeve, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Oscar B. Lahoud, David J. Chung, Sergio Giralt, Saad Z. Usmani, Ross S. Firestone
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3246–3253.
https://doi.org/10.1182/bloodadvances.2024012871
Published: 2024
Includes: Supplemental data
Journal Articles

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Clinical Trials & Observations
Issam S. Hamadeh, Tala Shekarkhand, Colin Rueda, Ross S. Firestone, Alice X. Wang, Neha Korde, Malin L. Hultcrantz, Alexander M. Lesokhin, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Kylee Maclachlan, Sridevi Rajeeve, Dhwani Patel, Gunjan L. Shah, Michael Scordo, Oscar B. Lahoud, David J. Chung, Heather J. Landau, Sergio Giralt, Saad Z. Usmani, Carlyn R. Tan
Journal: Blood Advances
Blood Adv (2024) 8 (12): 3038–3044.
https://doi.org/10.1182/bloodadvances.2024012724
Published: 2024
Journal Articles

CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

Ross S. Firestone, Devin McAvoy, Tala Shekarkhand, Edith Serrano, Issam Hamadeh, Alice Wang, Menglei Zhu, Wei Ge Qin, Dhwani Patel, Carlyn R. Tan, Malin Hultcrantz, Sham Mailankody, Hani Hassoun, Urvi S. Shah, Neha Korde, Kylee H. Maclachlan, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Oscar B. Lahoud, Sergio Giralt, Kazunori Murata, Kinga K. Hosszu, David J. Chung, Alexander M. Lesokhin, Saad Z. Usmani
Journal: Blood Advances
Blood Adv (2024) 8 (7): 1600–1611.
https://doi.org/10.1182/bloodadvances.2023011225
Published: 2024
Includes: Supplemental data
Journal Articles

Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population

Clinical Trials & Observations
Janine M. Joseph, Jens Hillengass, Li Tang, Alexander M. Lesokhin, Ola Landgren, Saad Z. Usmani, Kirsten B. Moysich, Susan E. McCann, Urvi A. Shah
Journal: Blood Advances
Blood Adv (2024) 8 (3): 538–548.
https://doi.org/10.1182/bloodadvances.2023011608
Published: 2024
Includes: Supplemental data
Journal Articles

Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies

Clinical Trials & Observations
Adam D. Cohen, Alfred L. Garfall, Ahmet Dogan, Simon F. Lacey, Chris Martin, Nikoletta Lendvai, Dan T. Vogl, Matthew Spear, Alexander M. Lesokhin
Journal: Blood Advances
Blood Adv (2019) 3 (16): 2487–2490.
https://doi.org/10.1182/bloodadvances.2019000466
Published: 2019
Journal Articles

Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition

Clinical Trials & Observations
Matthew J. Pianko, Sean M. Devlin, Eric R. Littmann, Aisara Chansakul, Donna Mastey, Meghan Salcedo, Emily Fontana, Lilan Ling, Elizabet Tavitian, John B. Slingerland, Ann E. Slingerland, Annelie Clurman, Antonio L. C. Gomes, Ying Taur, Eric G. Pamer, Jonathan U. Peled, Marcel R. M. van den Brink, Ola Landgren, Alexander M. Lesokhin
Journal: Blood Advances
Blood Adv (2019) 3 (13): 2040–2044.
https://doi.org/10.1182/bloodadvances.2019032276
Published: 2019
Includes: Supplemental data
Journal Articles

Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma

Clinical Trials & Observations
Ashraf Z. Badros, Ning Ma, Aaron P. Rapoport, Emily Lederer, Alexander M. Lesokhin
Journal: Blood Advances
Blood Adv (2019) 3 (11): 1658–1660.
https://doi.org/10.1182/bloodadvances.2019000191
Published: 2019